Literature DB >> 28181014

Long-term outcomes of totally implantable venous access devices.

Yi-Chia Wang1, Pei-Lin Lin1, Wei-Han Chou1, Chih-Peng Lin1,2, Chi-Hsiang Huang3.   

Abstract

PURPOSE: Identifying risk factors for premature totally implantable venous access device (TIVAD) catheter removal is crucial; however, because of the diversity of study methodologies, there is no consensus on such factors. The objective of the present study was to identify such risk factors by applying a cohort design study with a long-term follow-up period.
METHODS: For this cohort study, we selected cancer patients who had newly implanted TIVADs between July 2008 and December 2008. The follow-up period lasted until September 2012. Univariate analysis was performed for age, gender, cancer type, TIVAD brand, puncture site, sidedness of puncture, and catheter tip position. The hazard ratio (HR) of potential risk factors was calculated using the Cox proportional hazards regression model, and Kaplan-Meier curves were applied for catheter survival analysis.
RESULTS: Our study consisted of 240 people, with 5 people lost to follow-up. The cumulative premature catheter removal rate of all TIVADs was 9.8%, with the most common reason for premature removal being port-associated blood stream infection (PABSI), which proved to be highest in patients with hematology cancer (27.8%) and upper gastrointestinal cancer (19.4%). Suboptimal tip position (HR 5.13, 95% confidence interval 1.73-15.21) was also a risk factor for premature removal, and it was correlated with symptomatic TIVAD occlusion (p = 0.0004).
CONCLUSIONS: PABSI was the most common reason for premature catheter removal, with a varied incidence rate between different cancer types. Suboptimal tip position was also a risk factor. Confirming the final tip position after implantation is crucial. Infection control is important for TIVAD care, especially in high-risk cancer patients.

Entities:  

Keywords:  Catheter survival; Port-associated blood stream infection; Totally implantable venous access device

Mesh:

Year:  2017        PMID: 28181014     DOI: 10.1007/s00520-017-3592-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  27 in total

1.  Modification of approach for totally implantable venous access device decreases rate of complications.

Authors:  Hasan Karanlik; Sidika Kurul
Journal:  J Surg Oncol       Date:  2009-09-01       Impact factor: 3.454

2.  Totally implantable venous access device placement by interventional radiologists: are prophylactic antibiotics necessary?

Authors:  Anne M Covey; Franz W Toro-Pape; Raymond H Thornton; Crystal Son; Joseph Erinjeri; Constantinos T Sofocleous; Lynn A Brody; Karen T Brown; Kent A Sepkowitz; Kent A Septkowitz; George I Getrajdman
Journal:  J Vasc Interv Radiol       Date:  2012-03       Impact factor: 3.464

3.  Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.

Authors:  Akila Subramaniam; Kenneth H Kim; Shannon A Bryant; Kristopher J Kimball; Warner K Huh; J Michael Straughn; Jacob M Estes; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2011-07-13       Impact factor: 5.482

Review 4.  The complications of central venous access systems: a study of 218 patients.

Authors:  J R Torramadé; J A Cienfuegos; J L Hernández; F Pardo; C Benito; J González; E Balén; V de Villa
Journal:  Eur J Surg       Date:  1993 Jun-Jul

5.  Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers.

Authors:  Hsiang-Fong Kao; I-Chun Chen; Chiun Hsu; Sin-Yuan Chang; Shu-Fen Chien; Yee-Chun Chen; Fu-Chang Hu; James Chih-Hsin Yang; Ann-Lii Cheng; Kun-Huei Yeh
Journal:  Support Care Cancer       Date:  2014-01-03       Impact factor: 3.603

6.  The role of antibiotic prophylaxis in totally implantable venous access device placement: results of a single-center prospective randomized trial.

Authors:  Hasan Karanlik; Sidika Kurul; Pinar Saip; Ersin Selcuk Unal; Fatma Sen; Rian Disci; Erkan Topuz
Journal:  Am J Surg       Date:  2011-05-23       Impact factor: 2.565

7.  Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.

Authors:  R Biffi; F de Braud; F Orsi; S Pozzi; S Mauri; A Goldhirsch; F Nolè; B Andreoni
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

8.  Infections Related to Totally Implantable Venous-Access Ports: Long-Term Experience in One Center.

Authors:  Lijun Ji; Jinghua Yang; Jianzhong Miao; Qing Shao; Yuerong Cao; Hao Li
Journal:  Cell Biochem Biophys       Date:  2015-05       Impact factor: 2.194

9.  Incidence and risk factors for central venous access port-related infection in Chinese cancer patients.

Authors:  Ting-Yao Wang; Kuan-Der Lee; Ping-Tsung Chen; Min-Chi Chen; Yi-Yang Chen; Cih-En Huang; Feng-Che Kuan; Chih-Cheng Chen; Chang Hsien Lu
Journal:  J Formos Med Assoc       Date:  2015-08-05       Impact factor: 3.282

10.  Evaluation of infectious complications of the implantable venous access system in a general oncologic population.

Authors:  Lilu Chang; Jir-Shiong Tsai; Shin-Ju Huang; Chiang-Ching Shih
Journal:  Am J Infect Control       Date:  2003-02       Impact factor: 2.918

View more
  10 in total

1.  Late complications associated with totally implantable venous access port implantation via the internal jugular vein.

Authors:  Shigeaki Tsuruta; Yasutomo Goto; Hideo Miyake; Hidemasa Nagai; Yuichiro Yoshioka; Norihiro Yuasa; Junichi Takamizawa
Journal:  Support Care Cancer       Date:  2019-11-14       Impact factor: 3.603

2.  Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders.

Authors:  Christian J Hendriksz; Paul Harmatz; Roberto Giugliani; Jane Roberts; G Suren Arul
Journal:  Mol Genet Metab Rep       Date:  2018-03-07

3.  Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer.

Authors:  Liang Xu; Wenming Qin; Weiwei Zheng; Xingwei Sun
Journal:  World J Surg Oncol       Date:  2019-11-25       Impact factor: 2.754

4.  Cephalic vein approach for the implantable central venous access: A retrospective review of the single institution's experiences; Cohort Study.

Authors:  Jiyoung Rhu; Kang Woong Jun; Byung Joo Song; Kiyoung Sung; Jinbeom Cho
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  Safety and feasibility of 3-month interval access and flushing for maintenance of totally implantable central venous port system in colorectal cancer patients after completion of curative intended treatments.

Authors:  Sang-Bo Oh; Kwonoh Park; Jae-Joon Kim; So-Yeon Oh; Ki-Sun Jung; Byung-Soo Park; Gyung-Mo Son; Hyun-Sung Kim; Dong-Hyun Kim; Hyuk-Jae Jung; Sang-Su Lee
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

6.  Comparative structural analysis of polyurethane and silicone catheters of totally implantable venous access devices by micro-computed tomography.

Authors:  Daniele Panetta; Lara Tollapi; Adriana Paolicchi; Elisa Marri; Giacomo Aringhieri; Davide Caramella
Journal:  SAGE Open Med       Date:  2021-12-03

7.  Risk Factors of Catheter-Related Infection in Unplanned Extubation of Totally Implantable Venous-Accessportsin Tumor Patients.

Authors:  Min Xu; Lie Deng; Yanyi Zhu; Yuanfang Li; Fan Wang; Hui Li; Ying Zhou
Journal:  Emerg Med Int       Date:  2022-09-27       Impact factor: 1.621

8.  Experience in totally implantable venous port catheter: Analysis of 3,000 patients in 12 years.

Authors:  Fazlı Yanık; Yekta Altemur Karamustafaoğlu; Adem Karataş; Yener Yörük
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-07-03       Impact factor: 0.332

9.  Use of a hydrophilic coating wire reduces significantly the rate of central vein punctures and the incidence of pneumothorax in totally implantable access port (TIAP) surgery.

Authors:  Georgios Polychronidis; Roland Hennes; Cosima Engerer; Phillip Knebel; Daniel Schultze; Thomas Bruckner; Beat P Müller-Stich; Lars Fischer
Journal:  BMC Surg       Date:  2017-12-07       Impact factor: 2.102

10.  Comparison between ultrasound-guided TIVAD via the right innominate vein and the right internal jugular vein approach.

Authors:  Xingwei Sun; Xuming Bai; Jiaofeng Shen; Ziyang Yu; Zhixiang Zhuang; Yong Jin
Journal:  BMC Surg       Date:  2019-12-11       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.